AMSTERDAM, July 10, 2024 (GLOBE NEWSWIRE) -- This randomized, controlled trial
was conducted at a tertiary IVF center, Ho Chi Minh City, Vietnam. Between
January 2023 and June 2023, 120 women were randomized. Eligible women were aged
18-37 years with polycystic ovarian syndrome (PCOS). After providing written
informed consent, participants were randomized (1:1) to undergo CAPA-IVM with or
without FSH-priming. Participants in the FSH-priming group received two days of
recombinant FSH (rFSH) injections before oocyte pick-up; no rFSH was given in
the non-FSH group. All retrieved cumulus oocyte complexes underwent biphasic in
vitro maturation (CAPA-IVM). Matured oocytes underwent fertilization through
ICSI procedure, and were cultured to blastocyst stage followed by vitrification.
Participants underwent a single blastocyst transfer during a frozen replacement
cycle. The primary endpoint was the number of matured oocytes.
The number of matured oocytes after CAPA-IVM did not differ significantly
between the non-FSH and FSH groups (13 (9; 18) vs. 14 (7; 18); absolute
difference -1 (95% confidence interval -5, 4)). There were also no significant
between-group differences in other oocyte and embryology outcomes, including the
number of cumulus-oocyte complexes, number of fertilized oocytes, total number
of blastocysts and good blastocysts, and total number of frozen embryos. The
live birth rate was 38.3% in the non-FSH group and 31.7% in the FSH group, with
no statistically significant difference. The miscarriage rate at Â